Bacteria versus antibacterial agents: an integrated approach
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Washington, D.C.
ASM Press
2003
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Literaturangaben |
| Beschreibung: | XX, 393 S. Ill., graph. Darst. |
| ISBN: | 1555812589 |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV016548092 | ||
| 003 | DE-604 | ||
| 005 | 20101215 | ||
| 007 | t | ||
| 008 | 030225s2003 xxuad|| |||| 00||| eng d | ||
| 020 | |a 1555812589 |9 1-55581-258-9 | ||
| 035 | |a (OCoLC)51648181 | ||
| 035 | |a (DE-599)BVBBV016548092 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c US | ||
| 049 | |a DE-355 |a DE-11 |a DE-19 | ||
| 050 | 0 | |a RM409 | |
| 082 | 0 | |a 616.9/2061 |2 21 | |
| 084 | |a XI 3500 |0 (DE-625)152997:12905 |2 rvk | ||
| 100 | 1 | |a Mascaretti, Oreste A. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Bacteria versus antibacterial agents |b an integrated approach |c Oreste A. Mascaretti |
| 264 | 1 | |a Washington, D.C. |b ASM Press |c 2003 | |
| 300 | |a XX, 393 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Literaturangaben | ||
| 650 | 4 | |a Antibactériens | |
| 650 | 4 | |a Antibiose | |
| 650 | 7 | |a Antibióticos |2 larpcal | |
| 650 | 7 | |a Antiinfecciosos |2 larpcal | |
| 650 | 7 | |a Bacteriologia médica |2 larpcal | |
| 650 | 7 | |a Doenças infecciosas (imunologia) |2 larpcal | |
| 650 | 7 | |a Infecções bacterianas |2 larpcal | |
| 650 | 7 | |a Resistência microbiana às drogas |2 larpcal | |
| 650 | 4 | |a Anti-Infective Agents | |
| 650 | 4 | |a Antibacterial agents | |
| 650 | 4 | |a Antibiosis | |
| 650 | 4 | |a Bacteria |x drug effects | |
| 650 | 4 | |a Drug Resistance, Bacterial | |
| 650 | 0 | 7 | |a Bakterien |0 (DE-588)4004296-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Antibiotikum |0 (DE-588)4002257-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Bakterien |0 (DE-588)4004296-0 |D s |
| 689 | 0 | 1 | |a Antibiotikum |0 (DE-588)4002257-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010224480&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-010224480 | ||
Datensatz im Suchindex
| _version_ | 1804129857108443136 |
|---|---|
| adam_text | 0 ESS AN INTEGRATED APPROACH ORESTE A. MASCARETTI DEPARTMENT OF ORGANIC
CHEMISTRY FACULTY OF BIOCHEMISTRY AND PHARMACY UNIVERSIDAD NACIONAL DE
ROSARIO ROSARIO, ARGENTINA ASM PRESS WASHINGTON, D.C. CONTENTS FOREWORD
XV PREFACE XVII ACKNOWLEDGMENTS XIX CHAPTER 1 STRUCTURE AND FUNCTION OF
PROKARYOTIC AND EUKARYOTIC CELLS 1 CELLS AS THE BASIC UNITS OF LIFE 1
EUKARYOTIC AND PROKARYOTIC CELLS 2 EUKARYOTIC CELL ORGANIZATION 3 THE
PLASMA MEMBRANE 4 CYTOPLASMIC STRUCTURES 5 BACTERIAL MORPHOLOGY 7
BACTERIAL CELL ORGANIZATION 8 THE BACTERIAL CELL WALL 8 THE OUTER
MEMBRANE 17 THE PERIPLASMIC SPACE 22 THE CYTOPLASMIC MEMBRANE 22
CAPSULES AND SLIME LAYERS 24 ENDOSPORES 24 BACTERIAL CELL APPENDAGES 24
THE CYTOPLASMIC MATRIX 25 SUMMARY 28 THE BACTERIAL CELL WALL AND ITS
POLYMERS 29 BACTERIAL MEMBRANES, PORINS, AND THE PERIPLASMIC SPACE 29
VII VIII CONTENTS THE CYTOPLASM 29 THE NUCLEOID AND GENETIC ELEMENTS
APPENDAGES 30 REFERENCES AND FURTHER READING 30 29 CHAPTER 2* BACTERIAL
PATHOGENESIS 33 DEFINITIONS 33 BACTERIAL INVASION OF HUMAN CELLS STEPS
IN BACTERIAL INVASION 35 BACTERIAL ADHESION 35 TOXINS 37 BACTERIAL
TOXINS 37 VACCINES 39 SUPERANTIGENS 39 ENDOTOXINS 39 PATHOGENICITY
ISLANDS 40 BACTERIAL BIOFILMS 40 CONCLUDING REMARKS 40 REFERENCES AND
FURTHER READING 40 34 CHAPTER FI ESSENTIALS OF THE IMMUNE SYSTEM 43 THE
IMMUNE SYSTEM: AN OVERVIEW 44 IMMUNODEFICIENCIES 44 IMMUNOCOMPROMISED
HOSTS 44 INNATE IMMUNITY 44 ANATOMICAL BARRIERS 45 PHAGOCYTOSIS 46
INFLAMMATION 46 ADAPTIVE IMMUNITY 46 PASSIVE IMMUNITY 47 ACTIVE IMMUNITY
47 MECHANISMS OF THE ADAPTIVE IMMUNE RESPONSE IMMUNOGENS AND ANTIGENS 47
THE MAJOR HISTOCOMPATIBILITY COMPLEX 47 CELLS AND TISSUES OF THE IMMUNE
SYSTEM 48 CYTOKINES 54 ANTIBODIES 55 THE COMPLEMENT SYSTEM 58
OPSONIZATION AND PHAGOCYTOSIS 58 EXTRACELLULAR AND INTRACELLULAR
BACTERIA 58 EXTRACELLULAR BACTERIA 59 INTRACELLULAR BACTERIA 63
INTERACTIONS BETWEEN BACTERIA, IMMUNE DEFENSES, AND ANTIBACTERIAL DRUGS
64 ANTIBACTERIAL PENETRATION INTO EUKARYOTIC CELLS 64 SCHEMATIC
INTEGRATED OVERVIEW OF MECHANISMS OF HOST DEFENSE AGAINST BACTERIA 65
REFERENCES AND FURTHER READING 65 CHAPTER 4 69 MOLECULAR GENETICS OF
BACTERIA DEFINITIONS 69 REPLICATION OF THE BACTERIAL CHROMOSOME AND CELL
DIVISION 71 GENE EXPRESSION 71 THE GENETIC CODE 71 MUTATIONS 71 RATE OF
MUTATIONS IN BACTERIA 72 TYPES OF MUTATIONS 72 TRANSITION AND
TRANSVERSION MUTATIONS 73 MUTAGENS 73 GENETIC RECOMBINATION 76
EXTRACHROMOSOMAL GENETIC ELEMENTS 77 MOBILE GENE CASSETTES AND INTEGRONS
80 GENE TRANSFER 81 BACTERIAL CONJUGATION 81 DNA TRANSFORMATION 83
TRANSDUCTION 84 SIGNIFICANCE OF THE ORIGIN, TRANSMISSION, AND SPREAD OF
BACTERIAL RESISTANCE GENES 85 REFERENCES AND FURTHER READING 85 CHAPTER
.1 MECHANISMS OF BACTERIAL RESISTANCE TO THE 47 ACTION OF ANTIBACTERIAL
AGENTS 87 DEFINITION OF BACTERIAL RESISTANCE 87 BACKGROUND 87 HISTORICAL
PERSPECTIVE 88 CURRENT STATUS OF BACTERIAL RESISTANCE 88 CHARACTERISTICS
OF BACTERIAL RESISTANCE 88 SOURCES OF RESISTANCE GENES 88 DETECTION
METHODS 89 GENERAL MECHANISMS OF BACTERIAL RESISTANCE 89 CONTENTS IX
ACTIVE-EFFLUX MECHANISMS OF RESISTANCE 90 ENZYMATIC INACTIVATIONOF
ANTIBIOTICS BY MODIFICATION OF THEIR STRUCTURE 92 ALTERATION OF THE
TARGET SITE 93 REFERENCES AND FURTHER READING 94 CHAPTER R) ANTIBIOTICS
AND SYNTHETIC ANTIBACTERIAL AGENTS 97 DEFINITION OF ANTIBIOTICS 97
ANTIBIOTICS AND SYNTHETIC ANTIBACTERIAL AGENTS 97 CLASSIFICATION 98
CLASSIFICATION BY CHEMICAL STRUCTURE 98 CLASSIFICATION BY MECHANISM OF
ACTION 102 INDUSTRIAL PRODUCTION OF ANTIBIOTICS AND CLAVULANIC ACID 103
ISOLATION AND PURIFICATION OF ANTIBIOTICS PRODUCED BY FERMENTATION 105
REFERENCES AND FURTHER READING 105 CHAPTER 7 (3-LACTAMS,
PENICILLIN-BINDING PROTEINS, AND P-LACTAMASES 107 P-LACTAMS 107 P-LACTAM
ANTIBIOTICS 107 PENICILLIN-BINDING PROTEINS 111 CRYSTALLOGRAPHIC
STRUCTURE OF DD-PEPTIDASES: PENICILLIN TARGET ENZYMES 114 P-LACTAMASES
115 P-LACTAMASE NOMENCLATURE 115 P-LACTAMASE CLASSIFICATION 115 SERINE
P-LACTAMASES AND SERINE DD-TRANSPEPTIDASES 116 REFERENCES AND FURTHER
READING 124 CHAPTER O INHIBITORS OF PEPTIDOGLYCAN BIOSYNTHESIS:
PENICILLINS 129 HISTORICAL PERSPECTIVE ORI THE DEVELOPMENT OF
PENICILLINS AND P-LACTAMASE INHIBITORS 129 CLASSIFICATION OF THE
PENICILLINS 130 NATURAL PENICILLINS 131 ANTISTAPHYLOCOCCAL
P-LACTAMASE-RESISTANT PENICILLINS 132 AMINOPENICILLINS 134
ANTIPSEUDOMONAL PENICILLINS 135 PENICILLIN PREPARATIONS COMMERCIALLY
AVAILABLE IN THE UNITED STATES 137 REFERENCES AND FURTHER READING 137
CHAPTER J INHIBITORS OF PEPTIDOGLYCAN BIOSYNTHESIS: CEPHALOSPORINS 139
INTRODUCTION AND HISTORY OF DEVELOPMENT 139 CLASSIFICATION 140 CHEMICAL
TRANSFORMATION OF A PENICILLIN NUCLEUS TO A CEPHALOSPORIN NUCLEUS 141
3-SUBSTITUENT MODIFICATION 141 DEACYLATION BY ESTERASES OF THE
3 -ACETOXYMETHYL GROUP 142 CHEMICAL REACTIVITY OF THE P-LACTAM RING IN
CEPHALOSPORINS 142 DEPARTURE OF A LEAVING GROUP FROM C-3 OF
CEPHALOSPORIN MOLECULES 142 FIRST-GENERATION CEPHALOSPORINS 143
SECOND-GENERATION CEPHALOSPORINS 143 CEPHAMYCINS 144 CLINICAL USES OF
SPECIFIC SECOND-GENERATION CEPHALOSPORINS 144 MODIFICATIONS OF THE
CEPHEM NUCLEUS AT POSITION 3 146 MODIFICATIONS OF THE SIDE CHAIN OF
POSITION 7 OF THE CEPHEM NUCLEUS 146 MODIFICATIONS OF THE CEPHEM
NUCLEUS: CARBACEPHEMS AND OXACEPHEMS 146 MEANING OF THE TERM
GENERATION 146 THIRD-GENERATION CEPHAIOSPORINS 148 FOURTH-GENERATION
CEPHALOSPORINS 149 CHROMOGENIC CEPHALOSPORINS 151 CEPHALOSPORIN
PREPARATIONS COMMERCIALLY AVAILABLE IN THE UNITED STATES 151 REFERENCES
AND FURTHER READING 151 CHAPTER IU INHIBITORS OF PEPTIDOGLYCAN
BIOSYNTHESIS: CARBAPENEMS AND MONOBACTAMS 153 CARBAPENEMS 153 IMIPENEM
154 MEROPENEM 155 CONTENTS ERTAPENEM 155 CARBAPENEM PREPARATIONS
COMMERCIALLY AVAILABLE IN THE UNITED STATES 156 MONOBACTAMS ^,156
AZTREONAM 156 MONOBACTAM PREPARATION COMMERCIALLY AVAILABLE IN THE
UNITED STATES 157 REFERENCES AND FURTHER READING 157 CHAPTER I 1
P-LACTAM COMPOUNDS AS P-LACTAMASE INHIBITORS 159 NATURAL IRREVERSIBLE
INHIBITORS 159 CLAVULANIC ACID 159 SEMISYNTHETIC IRREVERSIBLE INHIBITORS
162 SULBACTAM 162 TAZOBACTAM 163 CLAVULANIC ACID, SULBACTAM, AND
TAZOBACTAM P-LACTAMASE-LNHIBITORY ACTIVITY 164 COMBINATIONS OF A
P-LACTAM ANTIBIOTIC AND A SERINE P-LACTAMASE INHIBITOR 165
AMOXICILLIN-POTASSIUM CLAVULANATE 165 TICARCILLIN-POTASSIUM CLAVULANATE
165 SODIUM AMPICILLIN-SODIUM SULBACTAM 166 SULTAMICILLIN 166
PIPERACILLIN-SODIUM TAZOBACTAM 166 CEFOPERAZONE-SULBACTAM 168
COMPARATIVE STUDIES OF THE ACTIVITY OF THE COMBINATIONS OF A P-LACTAM
ANTIBIOTIC AND A P-LACTAMASE INHIBITOR 168 COMBINATIONS OF A P-LACTAM
ANTIBIOTIC AND A P-LACTAMASE INHIBITOR COMMERCIALLY AVAILABLE IN THE
UNITED STATES 168 REFERENCES AND FURTHER READING 168 CHAPTER 1 -Z
BACTERIAL RESISTANCE TO P-LACTAM ANTIBIOTICS AND P-LACTAM INHIBITORS OF
P-LACTAMASES 171 EXTENDED-SPECTRUM P-LACTAMASES 172 TEM P-LACTAMASES 173
SHV-TYPE P-LACTAMASES 174 OXA-TYPE P-LACTAMASES 181 ALTERED
PENICILLIN-BINDING PROTEINS 181 FERN FACTORS 182 INDUCIBLE AMPC
P-LACTAMASES 182 RESEARCH AND DEVELOPMENTS IN NOVEL P-LACTAM ANTIBIOTICS
AND P-LACTAM INHIBITORS OF SERINE AND METAL LO-P-LACTAMASES 184 NEW
DEVELOPMENTS IN P-LACTAM ANTIBIOTICS 185 NEW DEVELOPMENTS IN INHIBITORS
OF SERINE AND METALLO-P-LACTAMASES 187 REFERENCES AND FURTHER READING
194 CHAPTER I . S INHIBITORS OF PEPTIDOGLYCAN BIOSYNTHESIS: FOSFOMYCIN
AND D-CYCLOSERINE 199 OVERVIEW OF BIOSYNTHESIS OF THE BACTERIAL
PEPTIDOGLYCAN UNIT 199 FOSFOMYCIN 199 MECHANISM OF ACTION 199 SPECTRUM
OF ANTIBACTERIAL ACTIVITY 200 CLINICAL USES 200 BACTERIAL RESISTANCE 200
FOSFOMYCIN PREPARATION COMMERCIALLY AVAILABLE IN THE UNITED STATES 202
D-CYCLOSERINE 202 MECHANISM OF ACTION 202 SPECTRUM OF ANTIBACTERIAL
ACTIVITY 202 CLINICAL USES 202 BACTERIAL RESISTANCE 202 REFERENCES AND
FURTHER READING 202 CHAPTER 14 INHIBITORS OF PEPTIDOGLYCAN BIOSYNTHESIS:
BACITRACIN AND GLYCOPEPTIDES 203 SUMMARY OF THE LAST STEPS OF
PEPTIDOGLYCAN BIOSYNTHESIS 203 BACITRACIN 204 MECHANISM OF ACTION 204
ANTIBACTERIAL ACTIVITY 205 CLINICAL USES 205 BACTERIAL RESISTANCE 205
BACITRACIN PREPARATIONS COMMERCIALLY AVAILABLE IN THE UNITED STATES 205
GLYCOPEPTIDES 205 CHEMICAL STRUCTURES OF VANCOMYCIN AND TEICOPLANINS 205
TARGET OF GLYCOPEPTIDE ANTIBIOTICS 206 CONTENTS XI ANTIBACTERIAL
ACTIVITY AND CLINICAL USES OFVANCOMYCIN 208 ANTIBACTERIAL ACTIVITY AND
CLINICAL USES OF TEICOPLANIN 209 BACTERIAL RESISTANCE 209 NOVEL
GLYCOPEPTIDE ANTIBIOTICS UNDER DEVELOPMENT 213 GLYCOPEPTIDE PREPARATION
COMMERCIALLY AVAILABLE IN THE UNITED STATES 214 REFERENCES AND FURTHER
READING 214 CHAPTER I / CHAPTER 1.1 ANTIBIOTICS THAT AFFECT MEMBRANE
PERMEABILITY: CYCLIC PEPTIDES 217 POLYMYXINS 217 MECHANISM OF ACTION 217
ANTIBACTERIAL ACTIVITY 217 CLINICAL USES 218 POLYMYXIN PREPARATIONS
COMMERCIALLY AVAILABLE IN THE UNITED STATES 218 REFERENCES AND FURTHER
READING 218 CHAPTER ANTIBIOTIC INHIBITORS OF BACTERIAL PROTEIN SYNTHESIS
219 PROTEIN SYNTHESIS: AN OVERVIEW 219 THE RIBOSOME AT ATOMIC RESOLUTION
219 X-RAY CRYSTAL STRUCTURE OF THE 70S RIBOSOME 220 X-RAY CRYSTAL
STRUCTURE OF THE 30S RIBOSOMAL SUBUNIT 220 X-RAY CRYSTAL STRUCTURE OF
THE 50S RIBOSOMAL SUBUNIT 220 TRNA STRUCTURE 221 PROTEIN SYNTHESIS 221
ACTIVATION OF AMINO ACIDS 221 INITIATION STEP IN PROKARYOTES 222
ELONGATION OF THE POLYPEPTIDE CHAIN 222 TERMINATION OF PROTEIN SYNTHESIS
224 NEWLY SYNTHESIZED POLYPEPTIDE CHAINS UNDERGO PROCESSING AND FOLDING
225 PROCESSING 225 FOLDING 225 ANTIBIOTICS THAT INHIBIT BACTERIAL
PROTEIN SYNTHESIS 225 REFERENCES AND FURTHER READING 227 INHIBITORS OF
THE 30S RIBOSOMAL SUBUNIT: AMINOGLYCOSIDES AND TETRACYCLINES 229
AMINOGLYCOSIDES 229 CHEMISTRY 230 SUMMARY OF CLINICAL USES 233 ADVERSE
EFFECTS 234 TRANSPORT THROUGH MEMBRANES 234 MECHANISM OF ACTION 234
BACTERIAL RESISTANCE 236 STRUCTURE-ACTIVITY RELATIONSHIPS AMONG
AMINOGLYCOSIDE DERIVATIVES 238 RECENT ADVANCES IN THE DEVELOPMENT OF
NOVEL AMINOGLYCOSIDES 239 AMINOGLYCOSIDE PREPARATIONS COMMERCIALLY
AVAILABLE IN THE UNITED STATES 239 TETRACYCLINES 239 HISTORY AND
OVERVIEW 239 CHEMICAL PROPERTIES 240 ANTIBACTERIAL ACTIVITY AND CLINICAL
USES 241 MECHANISM OF ACTION 242 TRANSPORT THROUGH MEMBRANES 242
BACTERIAL RESISTANCE 243 DEVELOPMENT OF NOVEL SEMISYNTHETIC
TETRACYCLINES 244 TETRACYCLINE PREPARATIONS COMMERCIALLY AVAILABLE IN
THE UNITED STATES 244 REFERENCES AND FURTHER READING 245 CHAP TER 18
INHIBITORS OF THE 50S RIBOSOMAL SUBUNIT: MACROLIDES, LINCOSAMIDES, AND
STREPTOGRAMINS 247 MACROLIDES 247 STRUCTURE AND CLASSIFICATION 247
HISTORICAL PERSPECTIVE ON RESEARCH TO DEVELOP NOVEL MACROLIDES 248 14-
AND 15-MEMBER RING MACROLIDES 248 CHEMICAL MODIFICATION AT THE
ERYTHRONOLIDE A 251 ROXITHROMYCIN 251 DIRITHROMYCIN 251 AZITHROMYCIN 252
CLARITHROMYCIN 253 16-MEMBER RING MACROLIDES 254 XII CONTENTS
INTRACELLULAR CONCENTRATION OF MACROLIDES 254 MECHANISM OF ACTION 255
MECHANISM OF BACTERIAL RESISTANCE 257 TRENDS IN MACROLIDE RESEARCH:
NOVEL MACROLIDES TO OVERCOME BACTERIAL RESISTANCE 259 MACROLIDE
PREPARATIONS COMMERCIALLY AVAILABLE IN THE UNITED STATES 261
LINCOSAMIDES 261 HISTORICAL PERSPECTIVE AND STRUCTURE OF LINCOMYCIN AND
CLINDAMYCIN 261 MECHANISM OF ACTION 262 ANTIMICROBIAL ACTIVITY AND
CLINICAL USES 263 BACTERIAL RESISTANCE 263 LINCOSAMIDE PREPARATIONS
COMMERCIALLY AVAILABLE IN THE UNITED STATES 263 STREPTOGRAMINS 263
HISTORICAL PERSPECTIVE 263 PRISTINAMYCINS IA AND IIA 263 QUINUPRISTIN
AND DALFOPRISTIN 265 ANTIMICROBIAL ACTIVITY AND CLINICAL USES 265
MECHANISM OF ACTION 266 BACTERIAL RESISTANCE 266 STREPTOGRAMIN
PREPARATIONS COMMERCIALLY AVAILABLE IN THE UNITED STATES 267 REFERENCES
AND FURTHER READING 267 CHAPTER 19 AN INHIBITOR OF THE 50S RIBOSOMAL
SUBUNIT: CHLORAMPHENICOL 273 STRUCTURE AND CURRENT STATUS OF CLINICAL
USES 273 STRUCTURAL FEATURES AND STRUCTURE-ACTIVITY RELATIONSHIPS 273
ANTIMICROBIAL ACTIVITY AND CLINICAL USES 274 MECHANISM OF ACTION 274
BACTERIAL RESISTANCE 275 ENZYMATIC INACTIVATION 275 ACTIVE EFFLUX 276
REFERENCES AND FURTHER READING 277 CHAPTER 2X) INHIBITORS OF THE
FORMATION OF THE FIRST PEPTIDE BOND: OXAZOLIDINONES 279 LINEZOLID 279
ANTIBACTERIAL ACTIVITY 280 CLINICAL USES 280 MECHANISM OF ACTION OF
OXAZOLIDINONES 280 BACTERIAL RESISTANCE 280 OXAZOLIDINONE PREPARATIONS
COMMERCIALLY AVAILABLE IN THE UNITED STATES 282 REFERENCES AND FURTHER
READING 282 CHAPTER -Z 1 AN INHIBITOR OF ISOLEUCYL-TRNA SYNTHETASE:
MUPIROCIN 285 ANTIMICROBIAL ACTIVITY 285 CLINICAL USES 286 MECHANISM OF
ACTION 286 BACTERIAL RESISTANCE 286 MUPIROCIN PREPARATIONS COMMERCIALLY
AVAILABLE IN THE UNITED STATES 287 REFERENCES AND FURTHER READING 287
CHAPTER R22 INHIBITORS OF DNA-DEPENDENT RNA POLYMERASE: RIFAMYCINS 289
OVERVIEW OF THE TRANSCRIPTION PROCESS 289 STRUCTURE OF BACTERIAL
DNA-DEPENDENT RNA POLYMERASE 290 RNA SYNTHESIS 290 CHEMISTRY OF
RIFAMYCINS 290 RIFAMPIN 291 MECHANISM OF ACTION 291 RESISTANCE 291
RIFABUTIN 292 RIFAPENTINE 292 RIFAMYCIN PREPARATIONS COMMERCIALLY
AVAILABLE IN THE UNITED STATES 292 REFERENCES AND FURTHER READING 292
CHAPTER INHIBITORS OF DNA GYRASE AND TOPOISOMERASE IV: QUINOLONES 295
BRIEF HISTORY AND OVERVIEW OF THE QUINOLONES 295 MECHANISM OF ACTION 297
SUPERCOILING 298 TOPOISOMERASES 298 CONTENTS XIII MODELS OF QUINOLONE
INTERACTIONS WITH DNAGYRASE 299 HIGH-RESOLUTION CRYSTAL STRUCTURE OF A
DOMAIN OF GYRA 301 STRUCTURE-ACTIVITY RELATIONSHIPS 302 ROUTES OF
QUINOLONE PERMEATION IN ESCHERICHIA COLI 302 CLINICAL USES OF FIRST-,
SECOND-, AND THIRD-GENERATION QUINOLONES AVAILABLE IN THE UNITED STATES
302 FIRST-GENERATION QUINOLONES 303 SECOND-GENERATION QUINOLONES 303
THIRD-GENERATION QUINOLONES 304 BACTERIAL RESISTANCE 305 DNA GYRASE 305
TOPOISOMERASE IV 306 RESISTANCE DUE TO ALTERED ACCESS OF DRUGS TO TARGET
ENZYMES 306 QUINOLONE PREPARATIONS COMMERCIALLY AVAILABLE IN THE UNITED
STATES 306 REFERENCES AND FURTHER READING 307 CHAPTER 24 ANTIBACTERIAL
AGENTS THAT CAUSE DNA DAMAGE IN OBLIGATE ANAEROBIC ORGANISMS:
5-NITROIMIDAZOLES 311 BRIEF HISTORY OF THE DEVELOPMENT OF
5-NITROIMIDAZOLES 311 METRONIDAZOLE 312 ANTIMICROBIAL ACTIVITY 312
MECHANISM OF ACTION 312 CLINICAL USES 313 FDA INDICATIONS 313 ACQUIRED
RESISTANCE 313 NITROIMIDAZOLE PREPARATIONS COMMERCIALLY AVAILABLE IN THE
UNITED STATES 314 REFERENCES AND FURTHER READING 314 CHAPTER
ANTIBACTERIAL AGENTS THAT CAUSE DAMAGE TO DNA: 5-NITROFURANS 315
NITROFURANTOIN 316 SPECTRUM OF ANTIMICROBIAL ACTIVITY 316 MECHANISM OF
ACTION 316 ACQUIRED RESISTANCE 316 CLINICAL USES 316 5-NITROFURAN
PREPARATIONS COMMERCIALLY AVAILABLE IN THE UNITED STATES 316 REFERENCES
AND FURTHER READING 317 CHAPTER COMPOUNDS THAT INTERFERE WITH
TETRAHYDROFOLIC ACID BIOSYNTHESIS: SULFONAMIDES AND TRIMETHOPRIM 319
SULFONAMIDE STRUCTURE 319 BRIEF HISTORY OF THE DEVELOPMENT OF
SULFONAMIDES AS ANTIBACTERIAL DRUGS 319 NOMENCLATURE 320
SULFAMETHOXAZOLE 321 I BIOSYNTHESIS OF SULFONAMIDES IN BACTERIA 321
MECHANISM OF ACTION OF SULFONAMIDES 321 INHIBITORS OF DIHYDROFOLATE
REDUCTASE 321 TRIMETHOPRIM 321 TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION
322 SPECTRUM OF ANTIMICROBIAL ACTIVITY 323 OVERVIEW OF THE MECHANISM OF
ACTION OF SULFONAMIDES AND TRIMETHOPRIM 323 TETRAHYDROFOLATE COFACTORS:
THE METABOLISM OF C X UNITS 323 A UNIQUE METHYLATION REACTION PRODUCES
DTMP FROM DUMP 323 PRECURSORS OF THE PURINE RING OF NUCLEOTIDES 323
BIOSYNTHESIS OF GLYCINE 323 BIOSYNTHESIS OF METHIONINE 323 CLINICAL USES
OF THE TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION 323 URINARY TRACT
INFECTIONS 323 RESPIRATORY TRACT INFECTIONS 323 GASTROINTESTINAL
INFECTIONS 324 OTHER INFECTIONS 325 TRIMETHOPRIM AND SULFONAMIDE
RESISTANCE 325 TRANSPORT-RELATED MECHANISMS 325 RESISTANCE TO
SULFONAMIDES 326 RESISTANCE TO TRIMETHOPRIM 326 SULFONAMIDES
COMMERCIALLY AVAILABLE IN THE UNITED STATES 327 REFERENCES AND FURTHER
READING 328 XIV CONTENTS CHAPTER X. / NEW ANTIBACTERIAL DRUGS IN
DEVELOPMENT THAT ACT ON NOVEL TARGETS 329 BACKGROUND AND OUTLOOK 329
NOVEL TARGETS 330 PEPTIDE DEFORMYLASE 330 ENZYME INHIBITORS AS DRUGS 331
AMIDE HYDROLYSIS: PEPTIDASES (PROTEASES) 331 TWO-COMPONENT SIGNAL
TRANSDUCTION IN BACTERIA 336 INHIBITORS OF TWO-COMPONENT REGULATORY
SYSTEMS IN BACTERIA 337 NOVEL ANTIBACTERIAL AGENTS BASED ON THE CYCLIC
DL-A-PEPTIDE ARCHITECTURE 338 ANTIMICROBIAL CATIONIC PEPTIDES 341
ANTIMICROBIAL CATIONIC PEPTIDES AND TOLL-LIKE RECEPTORS 341 BACTERIAL
FATTY ACID BIOSYNTHESIS 341 INHIBITORS OF BACTERIAL FATTY ACID
BIOSYNTHESIS 342 INHIBITORS OF BACTERIAL TYROSYL-TRNA SYNTHETASE 344
INHIBITORS OF THE ENZYMES OF THE DIAMINOPIMELATE PATHWAY 344 INHIBITORS
OF UDP-/V-ACETYLGLUCOSAMINE REDUCTASE (MURB) 345 INHIBITORS OF THE
BACTERIAL CELL WALL BIOSYNTHESIS ENZYME MURC 345 SELECTIVE CLEAVAGE OF
D-ALANYL-D-LACTIC ACID TERMINI OF PEPTIDOGLYCAN PRECURSORS 346
INHIBITORS OF BACTERIAL ADHESINS 346 (3-LACTAMS AS POTENTIAL INHIBITORS
OF PILUS ASSEMBLY IN PATHOGENIC BACTERIA 347 INHIBITORS OF LIPID A
BIOSYNTHESIS 347 BACTERIAL GENOME SEQUENCING AND ANTIBACTERIAL DRUG
DISCOVERY 348 NOVEL ANTIBACTERIAL COMPOUNDS IDENTIFIED BY USING
SYNTHETIC COMBINATORIAL LIBRARY TECHNOLOGY 348 HOW THE PHARMACEUTICAL
INDUSTRY BRINGS AN ANTIBACTERIAL DRUG TO THE MARKET IN THE UNITED STATES
349 CONCLUDING REMARKS AND OVERVIEW OF THIS CHAPTER 349 REFERENCES AND
FURTHER READING 349 EPILOGUE 355 APPENDIX A AMINO ACIDS, THE BUILDING
BLOCKS OF PROTEINS 357 APPENDIX B ENZYME CATALYSIS AND ENZYME INHIBITION
361 APPENDIX C LIPIDS AND MEMBRANES 367 APPENDIX D ANTIBIOTIC INFLUX AND
EFFLUX SYSTEMS 371 INDEX 379
|
| any_adam_object | 1 |
| author | Mascaretti, Oreste A. |
| author_facet | Mascaretti, Oreste A. |
| author_role | aut |
| author_sort | Mascaretti, Oreste A. |
| author_variant | o a m oa oam |
| building | Verbundindex |
| bvnumber | BV016548092 |
| callnumber-first | R - Medicine |
| callnumber-label | RM409 |
| callnumber-raw | RM409 |
| callnumber-search | RM409 |
| callnumber-sort | RM 3409 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| classification_rvk | XI 3500 |
| ctrlnum | (OCoLC)51648181 (DE-599)BVBBV016548092 |
| dewey-full | 616.9/2061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.9/2061 |
| dewey-search | 616.9/2061 |
| dewey-sort | 3616.9 42061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01952nam a2200541zc 4500</leader><controlfield tag="001">BV016548092</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20101215 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">030225s2003 xxuad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1555812589</subfield><subfield code="9">1-55581-258-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)51648181</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV016548092</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-11</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM409</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.9/2061</subfield><subfield code="2">21</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 3500</subfield><subfield code="0">(DE-625)152997:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mascaretti, Oreste A.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bacteria versus antibacterial agents</subfield><subfield code="b">an integrated approach</subfield><subfield code="c">Oreste A. Mascaretti</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C.</subfield><subfield code="b">ASM Press</subfield><subfield code="c">2003</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XX, 393 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibactériens</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibiose</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antibióticos</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antiinfecciosos</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bacteriologia médica</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Doenças infecciosas (imunologia)</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Infecções bacterianas</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Resistência microbiana às drogas</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anti-Infective Agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibacterial agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antibiosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bacteria</subfield><subfield code="x">drug effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Resistance, Bacterial</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Bakterien</subfield><subfield code="0">(DE-588)4004296-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antibiotikum</subfield><subfield code="0">(DE-588)4002257-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Bakterien</subfield><subfield code="0">(DE-588)4004296-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Antibiotikum</subfield><subfield code="0">(DE-588)4002257-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010224480&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-010224480</subfield></datafield></record></collection> |
| id | DE-604.BV016548092 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T19:11:48Z |
| institution | BVB |
| isbn | 1555812589 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-010224480 |
| oclc_num | 51648181 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-11 DE-19 DE-BY-UBM |
| owner_facet | DE-355 DE-BY-UBR DE-11 DE-19 DE-BY-UBM |
| physical | XX, 393 S. Ill., graph. Darst. |
| publishDate | 2003 |
| publishDateSearch | 2003 |
| publishDateSort | 2003 |
| publisher | ASM Press |
| record_format | marc |
| spelling | Mascaretti, Oreste A. Verfasser aut Bacteria versus antibacterial agents an integrated approach Oreste A. Mascaretti Washington, D.C. ASM Press 2003 XX, 393 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Literaturangaben Antibactériens Antibiose Antibióticos larpcal Antiinfecciosos larpcal Bacteriologia médica larpcal Doenças infecciosas (imunologia) larpcal Infecções bacterianas larpcal Resistência microbiana às drogas larpcal Anti-Infective Agents Antibacterial agents Antibiosis Bacteria drug effects Drug Resistance, Bacterial Bakterien (DE-588)4004296-0 gnd rswk-swf Antibiotikum (DE-588)4002257-2 gnd rswk-swf Bakterien (DE-588)4004296-0 s Antibiotikum (DE-588)4002257-2 s DE-604 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010224480&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Mascaretti, Oreste A. Bacteria versus antibacterial agents an integrated approach Antibactériens Antibiose Antibióticos larpcal Antiinfecciosos larpcal Bacteriologia médica larpcal Doenças infecciosas (imunologia) larpcal Infecções bacterianas larpcal Resistência microbiana às drogas larpcal Anti-Infective Agents Antibacterial agents Antibiosis Bacteria drug effects Drug Resistance, Bacterial Bakterien (DE-588)4004296-0 gnd Antibiotikum (DE-588)4002257-2 gnd |
| subject_GND | (DE-588)4004296-0 (DE-588)4002257-2 |
| title | Bacteria versus antibacterial agents an integrated approach |
| title_auth | Bacteria versus antibacterial agents an integrated approach |
| title_exact_search | Bacteria versus antibacterial agents an integrated approach |
| title_full | Bacteria versus antibacterial agents an integrated approach Oreste A. Mascaretti |
| title_fullStr | Bacteria versus antibacterial agents an integrated approach Oreste A. Mascaretti |
| title_full_unstemmed | Bacteria versus antibacterial agents an integrated approach Oreste A. Mascaretti |
| title_short | Bacteria versus antibacterial agents |
| title_sort | bacteria versus antibacterial agents an integrated approach |
| title_sub | an integrated approach |
| topic | Antibactériens Antibiose Antibióticos larpcal Antiinfecciosos larpcal Bacteriologia médica larpcal Doenças infecciosas (imunologia) larpcal Infecções bacterianas larpcal Resistência microbiana às drogas larpcal Anti-Infective Agents Antibacterial agents Antibiosis Bacteria drug effects Drug Resistance, Bacterial Bakterien (DE-588)4004296-0 gnd Antibiotikum (DE-588)4002257-2 gnd |
| topic_facet | Antibactériens Antibiose Antibióticos Antiinfecciosos Bacteriologia médica Doenças infecciosas (imunologia) Infecções bacterianas Resistência microbiana às drogas Anti-Infective Agents Antibacterial agents Antibiosis Bacteria drug effects Drug Resistance, Bacterial Bakterien Antibiotikum |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010224480&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT mascarettiorestea bacteriaversusantibacterialagentsanintegratedapproach |